Urology Times staff

“The…state of genomic testing continues to evolve,” says Ketan K. Badani, MD.

“What was surprising to us was that in both arms, about a third of the women really didn't have a urinary tract infection,” says Elizabeth R. Mueller, MD, MSME.

“I think as technology evolves, we as urologists need to continue to evolve and make changes to our practice,” says Kevin T. Keating, DO.

"I learned...over the first 10 years [of being married to a urologist] that everybody has a urology issue," says Madeline Zech Ruiz.

Pieczonka also discusses toxicity differences between VERU-111 and docetaxel.

“I think as these [advanced imaging] agents come out, we're going to see more and more data on this topic,” says Ketan K. Badani, MD.

The PSMA-PET imaging agents Piflufolastat F 18 and Gallium 68 PSMA-11 are approved by the FDA for managing patients with prostate cancer.

“We found in general that there was really no difference in their symptom improvement,” said Elizabeth R. Mueller, MD, MSME, of a study comparing women from whom standard vs expanded cultures were obtained.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer.

Christopher Pieczonka, MD, discusses where the novel agent sabizabulin (VERU-111) would fit in the metastatic castration-resistant prostate cancer paradigm if it succeeds in an ongoing phase 3 trial.

"There is clearly a lot of interest in the urologic oncology world toward bladder preservation for both muscle-invasive bladder cancer as well as early-stage non-muscle-invasive bladder cancer," says Arjun V. Balar, MD.

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.

Michael J. Morris, MD, discusses the rise of radiopharmaceuticals in prostate cancer and, in particular, the success of 177Lu-PSMA-617.

Wassim Abida, MD, PhD, discusses whether he would recommend PARP inhibitors in patients with metastatic castration-resistant prostate cancer harboring alterations in homologous recombination repair genes other than BRCA1/2.

“While many patients may think of imaging tests, as many other tests, as [having] a binary outcome, it may be important to have a discussion about how the scoring and MRI works, [and] what the patient can expect to see on their report,” says Stella K. Kang, MD.

Arjun V. Balar, MD, discusses notable findings from 2 separate studies of pembrolizumab (Keytruda).

“I think it's the responsibility of the physician to really take on educating and counseling and setting clear expectations and that way, when complications do arise, patients are better equipped, and they have a more favorable outcome,” says Ariana Matz, MD.

“What I found exciting was that the extent to which a…PI-RADS 4 score saved biopsies without really affecting the likelihood of detecting clinically significant tumor,” says Stella K. Kang, MD.

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”

Arjun V. Balar, MD, describes the 2 “very distinct patient populations” of separate phase 2 studies from ASCO 2021 involving the treatment pembrolizumab (Keytruda).

Brian T. Helfand, MD, PhD, discusses how the precision of genomic testing data can alleviate the accuracy issues associated with PSA testing for screening and monitoring prostate cancer.

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, explains the increased significance of genomic testing in the field of prostate cancer.

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses findings from the pivotal EV-301 trial of enfortumab vedotin.

"Same-day discharge is safe and feasible across a broad spectrum of FPMRS cases," says Jacqueline Zillioux, MD.

In this video, 5 urologists each weigh in on whether they listen to music in the OR, and if so, what they like to listen to.

Vinayak G. Wagaskar, MBBS, shares potential explanations for the obesity paradox in patients with metastatic castration-resistant prostate cancer and provides next steps for exploring this phenomenon.

Terrence Regan, MD, also discusses appropriate use criteria for advanced imaging from the Centers for Medicare & Medicaid Services.

“There's a lot that urologists can pick up on how to better interact with their patients,” says David King Keller, PhD, of Active Surveillance Patients International.

Evangelia Sereti, MSc, PhD, discusses the design/methodology and results of a preclinical study exploring the combination of the PARP inhibitor olaparib plus the novel agent NOV202 in BRCA1/2-mutated prostate cancer cells.

“[Prior authorization is] becoming a bigger and bigger problem for each practice,” says urologist Terrence Regan, MD.